Company Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States.
The company’s lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and PD-L1 checkpoint inhibitor antibodies.
It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A, as well as VEGF-IO Bispecific / Multiple, a bispecific antibody engages angiogenesis pathway and anti-tumor immune that targets immune checkpoints and analyzes VEGF combinations with other immune response-related proteins.
Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Country | United States |
Founded | 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 35 |
CEO | Thomas Schuetz |
Contact Details
Address: 80 Guest Street, Suite 601 Boston, Massachusetts 02135 United States | |
Phone | 617 500 8099 |
Website | compasstherapeutics.com |
Stock Details
Ticker Symbol | CMPX |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001738021 |
CUSIP Number | 20454B104 |
ISIN Number | US20454B1044 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Thomas J. Schuetz M.D., Ph.D. | Chief Executive Officer |
Vered Bisker-Leib MBA, Ph.D. | Advisor |
Barry Shin J.D. | Chief Financial Officer |
Jonathan Anderman J.D. | Senior Vice President, General Counsel and Corporate Secretary |
Anna Gifford | Communications Manager |
Dr. Minori Rosales M.D., Ph.D. | Senior Vice President and Head of Clinical Development |
Karin Herrera B.A. | Vice President and Head of Clinical Operations |
Dr. James Kranz Ph.D. | Vice President and Head of Chemistry Manufacturing and Controls |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
Feb 27, 2025 | 10-K | Annual Report |
Feb 27, 2025 | 8-K | Current Report |
Feb 14, 2025 | SCHEDULE 13G | Filing |
Feb 12, 2025 | SCHEDULE 13G/A | Filing |
Feb 4, 2025 | SCHEDULE 13G | Filing |
Jan 16, 2025 | SCHEDULE 13G | Filing |
Jan 8, 2025 | 8-K | Current Report |
Dec 10, 2024 | 8-K | Current Report |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |